drugset / Trial / NCT02266550

Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers

NCT02266550

Phase 1 Completed 6 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The aims of this phase I study are to define the metabolism, excretion and pharmacokinetics of \[14C\]-BIIL 284 BS after administration of a single oral dose of 25 mg \[14C\]-BIIL 284 BS in 6 healthy volunteers. Tolerability was also assessed.

Timeline

Start
1999-10
Primary completion
1999-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 25 mg Oral

Indications

No indication recorded.